Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label Promitil in BRCA/HRD-mutated pancreatic or ovarian cancer after first-line progression
MOH_2024-05-19_013416Phase 2Completed
- Sponsor
- LipoMedix
- Start
- Apr 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Mitomycin-c lipidic prodrug in pancreatic cancer (PC) and ovarian cancer, sponsored by LipoMedix. Started Apr 2024; status: completed.
02
Drugs
Mitomycin-c lipidic prodrug
03
Conditions
pancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on MOH_2024-05-19_013416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-19_013416.